With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

On April 3, 2017, Susan Keown, of Fred Hutch News, published an article on updated data from the research team behind the pivotal trial of avelumab in metastatic, treatment-resistant MCC. The data presented from their study shows the drug has gone on to break even its own impressive record in these patients.

Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma

Click here to view the article.